Overview


According to FutureWise analysis the market for onchocerciasis treatment is expected to register a CAGR of 11% from 2023-2031

Onchocerciasis is also known as river blindness and is caused by an infection with the parasitic Worm Onchocerca Volvulus. Itching bumps under the skin and blindness are some of the symptoms. After trachoma, it is the second most common cause of blindness caused by infection. Black fly Simulium types are the vectors of parasite worms. It is common to get many bites before infection occurs. The common name for the disease is because these flies are found near rivers. The worms can become larvae and infect other people by transferring their genes to the skin. You can diagnose the disease by taking a skin biopsy and then watching for the larvae to emerge. Also, you can look under the skin to check for adult worms. There is no vaccine to prevent the disease. Avoiding being bitten by insects is the best way to prevent this disease. You can prevent flies from biting you by using insect repellents and appropriate clothing. Spraying insecticides can also be used to reduce the fly population. In many parts of the world, efforts are ongoing to eradicate the disease by treating whole populations twice per year. The medication ivermectin is used to treat those who are infected every six to twelve months. The treatment only kills the larvae but does not affect the adult worms. Some recommend the antibiotic doxycycline, which weakens the worms and kills an associated bacterium called Wolbachia. Surgery may be performed to remove the lumps beneath the skin.
Ivermectin (tradename: Mectizan) is the treatment for onchocerciasis in mass drug administration (MDA). Infected individuals can receive two doses of ivermectin every six months, and then another dose every three years. It paralyzes and kills microfilariae, causing itching, fever, arthritis, and possible edema. The drug stops the progression to blindness by easing intense skin itching. The drug doesn't kill adult worms but it does stop them from producing more offspring for a short time. The drug doesn't prevent the transmission of Onchocerciasis. However, it reduces mortality and has been shown to eliminate some endemic regions of Africa. It is a quick and easy treatment that can be administered by community health workers. The onchocerciasis treatment industry has seen a rise in demand over recent years. This is due to the rising market capitalization of smaller companies, the growing number of strategic partnerships to grab the best of new medications or drugs, increased R D expenditure by big pharma, emerging players, expanded indications of approved drugs, and increasing competition among companies producing drugs for the same indications. The African Program for Onchocerciasis Control has started a detailed assessment of the long-term effect of ivermectin treatments and the possibility of reaching an end in APOC-recognized countries. The market is expected to grow due to the availability of generic drugs that treat onchocerciasis. Additional positive factors that will accelerate the growth of the market for onchocerciasis treatment include the increasing focus of emerging governments on developing healthcare infrastructure and raising awareness about the condition.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Onchocerciasis Treatment Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Onchocerciasis Treatment Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Meck and Co Inc
  • Mayne Pharma Group
  • Par Pharmaceutical Companies Inc
  • Delta Pharma Ltd
  • Life Pharmaceutical
  • Taj Pharmaceutical Limited

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drugs

  • Storomectol (oral)
  • Ivermectin (oral)

By End-User

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Onchocerciasis Treatment Market By Drugs, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Onchocerciasis Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Onchocerciasis Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Onchocerciasis Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Onchocerciasis Treatment Market, By Drugs Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Storomectol (oral)
        2. Ivermectin (oral)

  • 8.   Onchocerciasis Treatment Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Others

  • 9.   North America Onchocerciasis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Onchocerciasis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Onchocerciasis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Onchocerciasis Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Meck and Co Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Mayne Pharma Group
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Par Pharmaceutical Companies Inc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Delta Pharma Ltd
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Life Pharmaceutical
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Taj Pharmaceutical Limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients